Pignata S, et al. - In order to examine the safety of cetuximab (CET), an anti-epidermal growth factor receptor (EGFR) antibody, in combination with carboplatin (C) and paclitaxel (P), a standard treatment for advanced/recurrent cervical cancer (ARCC) patient, researchers randomized ARCC patients, ECOG PS ≤ 1, to CP for 6 cycles with or without CET (400 mg/m² one week before starting CP, then 250 mg/m² weekly) until disease progression or unacceptable toxicity. They assigned 108 patients to CP (n = 53) or CP-CET (n = 55). Outcomes suggest no higher activity of CP-CET vs CP alone in unselected ARCC patients. Biomarker analysis, in a small subgroup of patients, suggests the possible predictive value of PIK3CA mutation for CET resistance.